Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Tariff Resilience Score: 0/10 (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$474.40
GF Value HK$258.77
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Tariff Resilience Score?

Sichuan Kelun-Biotech Biopharmaceutical Co has the Tariff Resilience Score of 0, which implies that the company might have .

Sichuan Kelun-Biotech Biopharmaceutical Co has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Sichuan Kelun-Biotech Biopharmaceutical Co might have .

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Sichuan Kelun-Biotech Biopharmaceutical Co Tariff Resilience Score Related Terms

HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$474.40 is trading 83.3% above its estimated GF Value™ of HK$258.77. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Tariff Resilience Score: 0
  • GF Value™: HK$258.77 vs. price of HK$474.40 (83.3% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$474.40
Price
HK$258.77
GF Value